# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYASSAY AND INSTRUMENT

I Background Information:

# C Proprietary and Established Names

LIAISON VZV IgG HT, LIAISON Control VZV IgG HT

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LFY</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3900 -Varicella-Zoster VirusSerological Reagents</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: Clearance of a new device.   
B Measurand: Human IgG antibodies specific to Varicella Zoster Virus (VZV).   
C Type of Test: Chemiluminescence Immunoassay (CLIA) Technology.

# III Intended Use/Indications for Use:

# A Intended Use(s):

The LIAISON VZV IgG HT assay uses chemiluminescent immunoassay (CLIA) technology for the in vitro qualitative detection of specific IgG antibodies to varicella-zoster virus (VZV) in human serum (with gel and without gel-SST), dipotassium EDTA (K2- EDTA), lithium heparin and sodium heparin plasma samples. This assay is intended as an aid in the determination of

previous infection of varicella-zoster virus. The test must be performed on the LIAISON XL Analyzer. The assay performance in detecting antibodies to VZV in individuals vaccinated with the FDA-licensed VZV vaccine is unknown. The user of this assay is responsible for establishing the performance characteristics with VZV vaccinated individuals.

B Indication(s) for Use: See Intended Uses above.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

D Special Instrument Requirements: The LIAISON XL Analyzer.

IV Device/System Characteristics:

# A Device Description:

The LIAISON VZV IgG HT assay requires the use of reagents specific for VZV IgG immunoassay and the recommended LIAISON Control VZV IgG HT. The reagent and calibrators are packaged together in the LIAISON VZV IgG HT kit, while the LIAISON Control VZV IgG HT is packaged separately. The assay is performed on the LIAISON XL Analyzer, a fully automated system with continuous loading system that performs the complete sample processing (sample pre-dilutions, sample and reagent dispensing, incubations, wash processes) and the measurement and evaluation.

The assay contains different components: reagent integral (magnetic particles, conjugate, assay buffer, and calibrator), and external controls (positive and negative).

# B Principle of Operation:

The LIAISON VZV IgG HT assay is an indirect chemiluminescence immunoassay (CLIA) used for the qualitative detection of specific IgG antibodies to varicella-zoster virus (VZV). During the first incubation with the magnetic particles, anti-VZV antibodies, if present in calibrators, samples, or controls, bind to VZV antigen coated on magnetic particles (solid phase). During the second incubation, the antibody conjugate (anti-human mouse monoclonal antibody conjugated to isoluminol derivative) reacts with any human anti-VZV IgG already bound to the solid phase. After each incubation, the unbound material is removed with a wash cycle. Subsequently, the starter reagents are added and a flash chemiluminescence reaction is thus induced. The light signal, and hence the amount of isoluminol-antibody conjugate in the sample, is measured by a photomultiplier as relative light units (RLU) and is indicative of the presence of absence of antiVZV IgG antibodies in calibrators, samples, or controls.

Interpretation of Results: The presence or absence of VZV IgG antibodies in the specimens is determined by comparing the chemiluminescence reaction signal to the cut-off value provided by the assay calibration. The LIAISON XL analyzer automatically calculates the signal-to-cutoff (S/CO) ratios, and interprets the results as presented in Table 1.

Table 1: LIAISON VZV IgG HT Results Interpretation   

<table><tr><td rowspan=1 colspan=1>S/CO</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Interpretation</td></tr><tr><td rowspan=1 colspan=1>&lt; 1.00</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>A result below 1.00 S/CO may indicate the absence, or a level of IgGantibodies to VZV below the threshold.</td></tr><tr><td rowspan=1 colspan=1>≥1.00</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>A result above or equal to 1.00 S/CO generally indicates exposure of thesubject to VZV.</td></tr></table>

# C Instrument Description Information:

1. Instrument Name: LIAISON XL Analyzer

2. Specimen Identification: Specimen identification is automated using LIAISON XL Analyzer. The assay is intended for use with the following matrices: Serum (with gel and without gel-SST), dipotassium EDTA (K2- EDTA), lithium heparin and sodium heparin plasma.

V Substantial Equivalence Information:

A Predicate Device Name(s): LIAISON VZV IgG, LIAISON Control VZV IgG   
B Predicate 510(k) Number(s): K150375

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="2">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">Predicate</td><td colspan="1" rowspan="1">Candidate Device</td></tr><tr><td colspan="1" rowspan="1">K150375</td><td colspan="1" rowspan="1">K231214</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">LIAISON VZV IgG</td><td colspan="1" rowspan="1">LIAISON VZV IgG HT</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Technology/Assay Principle</td><td colspan="1" rowspan="1">Chemiluminescent Immunoassay(CLIA)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Handling/AssayProcessing</td><td colspan="1" rowspan="1">Automated</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Manufacturing Process</td><td colspan="1" rowspan="1">No Change</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">Store at 2-8° C until ready to use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measured</td><td colspan="1" rowspan="1">IgG antibodies to Varicella-zostervirus</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">20 μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">•  Dispense calibrators, controls,or samples</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Assay Procedure</td><td colspan="1" rowspan="1">Dispense magnetic particlesDispense specimen diluentIncubateWashDispense conjugateIncubateWashDispense starter reagentMeasure Light emitted(RLUs)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measurement System</td><td colspan="1" rowspan="1">Photomultiplier (flashchemiluminescence reader)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Included with kit</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Open Use/On BoardStability</td><td colspan="1" rowspan="1">Eight (8) weeks at 2-8°C oronboard the analyzer</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration Stability</td><td colspan="1" rowspan="1">Eight (8) weeks</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Provided Separately</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Storage at</td><td colspan="1" rowspan="1">Seven (7) days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Serum Storage Freeze-Thaw Cycles</td><td colspan="1" rowspan="1">5 freeze-thaw cycles</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">The DiaSorin LIAISON VZVIgG uses chemiluminescenceimmunoassay (CLIA) technologyon the LIAISON Analyzer familyfor the qualitative detection ofspecific IgG antibodies tovaricella-zoster virus (VZV) inhuman serum. This assay can beused as an aid in thedetermination of previousinfection of varicella-zoster virus.The assay performance indetecting antibodies to VZV inindividuals vaccinated with theFDA licensed VZV vaccine isunknown. The user of this assayis responsible for establishing theperformance characteristics withVZV vaccinated individuals.</td><td colspan="1" rowspan="1">The LIAISON VZV IgG HTassay uses chemiluminescentimmunoassay (CLIA) technologyfor the in vitro qualitativedetection of specific IgGantibodies to varicella-zostervirus (VZV) in human serum(with gel and without gel-SST),dipotassium EDTA (K2- EDTA),lithium heparin and sodiumheparin plasma samples. Thisassay is intended as an aid in thedetermination of previousinfection of varicella-zoster virus.The test must be performed onthe LIAISON XL Analyzer. Theassay performance in detectingantibodies to VZV in individualsvaccinated with the FDA-licensed VZV vaccine isunknown. The user of this assayis responsible for establishing theperformance characteristics with</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">VZV vaccinated individuals.</td></tr><tr><td colspan="1" rowspan="1">Reagent IntegralConfiguration(1 compartment eachreagent)</td><td colspan="1" rowspan="1">Magnetic particlesCalibrator 1Calibrator 2Specimen Diluent•   Conjugate</td><td colspan="1" rowspan="1">Magnetic particlesCalibratorAssay BufferConjugate</td></tr><tr><td colspan="1" rowspan="1">Raw Materials</td><td colspan="1" rowspan="1">•   Antigen: Inactivatedvaricella-zoster virus lysate(ROD strain)Detector: Mouse monoclonalanti-human IgG conjugated toisoluminol derivativeCapture: Magneticmicroparticles coated withvaricella-zoster antigen</td><td colspan="1" rowspan="1">Antigen: purified VaricellaZoster Virus glycoproteinDetector: sameCapture: Magnetic particlescoated with varicella ZosterVirus glycoprotein</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Human Serum</td><td colspan="1" rowspan="1">Human Serum and Plasma</td></tr><tr><td colspan="1" rowspan="1">Tests per Kit</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">200</td></tr><tr><td colspan="1" rowspan="1">Cut-Off</td><td colspan="1" rowspan="1">150 Index value</td><td colspan="1" rowspan="1">1.00 S/CO</td></tr><tr><td colspan="1" rowspan="1">Equivocal Zone</td><td colspan="1" rowspan="1">135-165 Index Value</td><td colspan="1" rowspan="1">No equivocal zone</td></tr><tr><td colspan="1" rowspan="1">Reagent Volume Provided</td><td colspan="1" rowspan="1">Magnetic particles (2.5 mL)Conjugate (23 mL)</td><td colspan="1" rowspan="1">Magnetic particles (2.45 mL)Conjugate (28.5 mL)</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Two-point verification of storedmaster curve</td><td colspan="1" rowspan="1">Calibration by using fullyqualitative approach with onecalibrator</td></tr><tr><td colspan="1" rowspan="1">Unit of Measure</td><td colspan="1" rowspan="1">Index Value</td><td colspan="1" rowspan="1">Signal/Cut-off (S/CO)</td></tr></table>

# VI Standards/Guidance Documents Referenced:

Standard/Guidance Documents referenced are below:

CLSI EP05-A3 Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline -Third Edition (2014).   
CLSI EP07 lnterference Testing in Clinical Chemistry; Approved Guideline-Third Edition (2018).   
CLSI EP37 Supplemental Tables for Interference Testing in Clinical Chemistry-First Edition.   
CLSI EP15-A3 User Verification of Precision and Estimation of Bias; Approved Guideline – Third Edition (Reaffirmed: September 2019).   
CLSI EP25-A Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline (2009).   
ISO 14971-Medical Devices-Application of risk management to medical devices-Third Edition. (2019).

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

Within-Laboratory Precision: A 20-day within-laboratory precision study was performed using 3 lots of LIAISON VZV IgG HT reagent integrals and LIAISON Control VZV IgG HT. Study was conducted within a single calibration cycle. Within laboratory precision results are reported in table below.

Table 2: LIAISON VZV IgG HT Assay Within-Laboratory Precision   

<table><tr><td rowspan=2 colspan=1>Sample ID</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(C)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>NegativeControl A</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.0166</td><td rowspan=1 colspan=1>0.0012</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>0.0017</td><td rowspan=1 colspan=1>10.4%</td><td rowspan=1 colspan=1>0.0021</td><td rowspan=1 colspan=1>13.0%</td><td rowspan=1 colspan=1>0.0021</td><td rowspan=1 colspan=1>12.8%</td><td rowspan=1 colspan=1>0.0034</td><td rowspan=1 colspan=1>20.7%</td></tr><tr><td rowspan=1 colspan=1>NegativeConlontrol B</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.0150</td><td rowspan=1 colspan=1>0.0018</td><td rowspan=1 colspan=1>11.9%</td><td rowspan=1 colspan=1>0.0014</td><td rowspan=1 colspan=1>9.6%</td><td rowspan=1 colspan=1>0.0020</td><td rowspan=1 colspan=1>13.2%</td><td rowspan=1 colspan=1>0.0023</td><td rowspan=1 colspan=1>15.3%</td><td rowspan=1 colspan=1>0.0035</td><td rowspan=1 colspan=1>23.5%</td></tr><tr><td rowspan=1 colspan=1>PositiveControl A</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>3.73</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.076</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.211</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>0.206</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>0.285</td><td rowspan=1 colspan=1>7.6%</td></tr><tr><td rowspan=1 colspan=1>PositiveControl B</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>3.57</td><td rowspan=1 colspan=1>0.079</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.089</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.216</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>0.193</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>0.289</td><td rowspan=1 colspan=1>8.1%</td></tr><tr><td rowspan=1 colspan=1>PositiveControl C</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>3.49</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.078</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.199</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>0.210</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.279</td><td rowspan=1 colspan=1>8.0%</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.120</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>7.1%</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>8.5%</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.669</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>7.0%</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.850</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.036</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>7.7%</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>8.2%</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.055</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.037</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.072</td><td rowspan=1 colspan=1>5.7%</td></tr><tr><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>3.33</td><td rowspan=1 colspan=1>0.071</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.151</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>0.099</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.190</td><td rowspan=1 colspan=1>5.7%</td></tr><tr><td rowspan=1 colspan=1>Sample 6</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>6.84</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>5.4%</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>5.0%</td></tr></table>

Reproducibility Study (multi-site precision): A 5-day reproducibility study was performed at 3 US sites, using 1 test lot. Results of the Reproducibility study for the LIAISON VZV IgG HT Assay performed across three sites are presented in the tables below.

Table 3: LIAISON VZV IgG HT Assay Reproducibility   

<table><tr><td rowspan=2 colspan=1>Sample ID</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(S/CO)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Between Site</td><td rowspan=1 colspan=2>Reproducibility</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>NegativeL Control</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>9.1%</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>7.6%</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>13.0%</td></tr><tr><td rowspan=1 colspan=1>PositiveControl</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>3.55</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.135</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.121</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.201</td><td rowspan=1 colspan=1>5.7%</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0.108</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>9.4%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>10.4%</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0.638</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>6.6%</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.050</td><td rowspan=1 colspan=1>7.8%</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0.783</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>8.1%</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.079</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>0.063</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>0.104</td><td rowspan=1 colspan=1>8.8%</td></tr><tr><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>3.31</td><td rowspan=1 colspan=1>0.143</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.176</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>0.172</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.267</td><td rowspan=1 colspan=1>8.1%</td></tr><tr><td rowspan=1 colspan=1>Sample 6</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>6.95</td><td rowspan=1 colspan=1>0.279</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.187</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.240</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.388</td><td rowspan=1 colspan=1>5.6%</td></tr><tr><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>0.446</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.427</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.509</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.756</td><td rowspan=1 colspan=1>5.7%</td></tr></table>

2. Linearity:

Not applicable.

3. Analytical Specificity/Interference:

a. Potential Cross-Reactivity:

Potential cross-reactivity for the LIAISON VZV IgG HT assay was determined by testing specimens (serum, K2 EDTA plasma and Li Heparin plasma samples) from individuals with antibodies to different microorganisms or with other medical conditions unrelated to VZV (bacterial and viral infections as well as autoimmune disorders). No false positive results were observed. The data provided showed no cross-reactivity with the potential crossreactants tested.

Table 4: LIAISON VZV IgG HT Assay Cross-Reactivity study   

<table><tr><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=1>Potential Cross reactants</td><td rowspan=1 colspan=1>Number of tested samples</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>CMV (anti-CMV positive)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Epstein-Bar Virus (anti-EBV positive)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Herpes Simplex Virus (anti-HSV 1positive</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Herpes Simplex Virus (anti-HSV 2positive</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Rubella (anti-Rubella positive)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Hepatitis C Virus (anti-HCV positive)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Human Immunodeficiency Virus (anti-HIV antibodies)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Hepatitis A Virus (anti-HAV positive)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Borrelia burgdorferi (anti-B. burgorferiantibodies)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Toxoplasma. Gondii (anti-T. gondiiantibodies)</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>Parvovirus B19 (anti-Parvovirus B19positive)</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>Measles virus (anti-Measles antibodies)</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>Mumps virus (anti-Mumps antibodies)</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>Adenovirus (anti-Adenovirus antibodies)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>Anti-Influenza A antibodies</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>Anti-Influenza B antibodies</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>Mycoplasma pneumonia (anti-M.pneumonia antibodies)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>Respiratory syncytial virus (RSV)antibodies</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>Human anti-mouse antibodies (HAMA)</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>Anti-nuclear antibodies (ANA)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>TOTAL</td><td rowspan=1 colspan=1>226</td></tr></table>

b. Endogenous and Exogenous Interfering Substances:

The LIAISON VZV IgG HT assay was evaluated for potential interference caused by endogenous and exogenous substances using VZV IgG antibody-negative, high negative, around the cut-off, low positive, and high positive samples. No interference was observed with the endogenous and exogenous interference substances at the concentration listed in the table below.

Table 5: Endogenous and Exogenous Interfering Substances Evaluated   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentrations tested</td></tr><tr><td rowspan=1 colspan=2>Endogenous Substances</td></tr><tr><td rowspan=1 colspan=1>Unconjugated bilirubin</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Conjugated bilirubin</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>3000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Human Serum Albumin</td><td rowspan=1 colspan=1>6000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>400 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Total IgG</td><td rowspan=1 colspan=1>2000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Total IgM</td><td rowspan=1 colspan=1>400 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Total protein (high)</td><td rowspan=1 colspan=1>≥ 120 g/L</td></tr><tr><td rowspan=1 colspan=1>Total protein (low)</td><td rowspan=1 colspan=1>≤ 60 g/L</td></tr><tr><td rowspan=1 colspan=1>Human anti-mouse antibody (HAMA)</td><td rowspan=1 colspan=1>820 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (RF)</td><td rowspan=1 colspan=1>2000 IU/mL</td></tr><tr><td rowspan=1 colspan=2>Exogenous Substances</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>3500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Vitamin A</td><td rowspan=1 colspan=1>800 μg/dL</td></tr><tr><td rowspan=1 colspan=1>Vitamin B12</td><td rowspan=1 colspan=1>2850 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Vitamin C</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Vitamin D</td><td rowspan=1 colspan=1>450 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Vitamin E</td><td rowspan=1 colspan=1>120 mg/L</td></tr><tr><td rowspan=1 colspan=1>Folic Acid</td><td rowspan=1 colspan=1>160 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>15.6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>21.9 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Naproxen</td><td rowspan=1 colspan=1>36.0 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Penicillin</td><td rowspan=1 colspan=1>110 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Streptomycin (sulphate)</td><td rowspan=1 colspan=1>25.8 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>13.8 mg/dL</td></tr></table>

4. Assay Reportable Range: Not Applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): Not Applicable.

6. Detection Limit: Not applicable.

7. Assay Cut-Off:

The study was performed to determine the LIAISON VZV IgG HT assay S/CO cutoff. A total of 90 samples with 42 VZV IgG antibody negative samples, and 48 VZV IgG antibody positive samples were included. A receiver-operator curve analysis showed a clear separation of the non-reactive and reactive results using a cut-off of $1 . 0 0 \ : \mathrm { S / C O }$ value.

# 8. Analytical Sensitivity at cutoff:

The analytical sensitivity of the LIAISON VZV IgG HT assay was determined using a series of serial dilutions of the WHO First International Standard for varicella zoster immunoglobulin (1987), NIBSC code: W1044 in negative serum matrix. Three lots of the LIAISON VZV IgG HT assay were used. The data was analyzed by regression analysis, considering the best fit. The cut-off in $\mathrm { m U / m L }$ was identified as the corresponding to 1.00 S/CO on the regression analysis. The analytical sensitivity at the cutoff is the higher concentration among the 3 lots for the reference standard that corresponds to the cut-off value of 1.00 S/CO for LIAISON VZV IgG HT assay is $0 . 1 5 2 4 ~ \mathrm { I U / m L }$ ( $1 5 2 . 4 \mathrm { m I U / m L } )$ .

9. Accuracy (Instrument): Not applicable

10. Sample Carry-Over: The LIAISON VZV IgG HTis not susceptible to within-assay sample carry-over.

# B Comparison Studies:

1. Method Comparison Study:

# Clinical Agreement Study:

A multisite clinical agreement study was conducted to evaluate the clinical performance of the LIAISON VZV IgG HT test. One thousand five hundred and forty-four (1544) clinical human serum samples were used for this study, including 125 known positive specimens, 200 known negative specimens, 135 pregnant women specimens and 1084 specimens sent to the laboratory for testing.

The samples were collected within the United States and tested at three independent external laboratories. Each sample, was tested with the LIAISON VZV IgG HT test and the comparator. The positive and negative percent agreements were calculated and presented below for normal laboratory routine (all), normal laboratory routine pediatric, and pregnant women. Specimens which were repeatedly equivocal by the predicate device were graded against the performance of the LIAISON VZV IgG HT assay which does not have an equivocal zone. The results for all populations are shown in the tables below.

Table 6: Known Positive Specimens $\mathrm { ( n { = } 1 2 5 }$ )   

<table><tr><td rowspan=2 colspan=1>LIAISON VZV IgG HT</td><td rowspan=1 colspan=3>Comparator</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>123</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>125</td></tr><tr><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=2>99.2% (123/124)</td><td rowspan=1 colspan=2>95%CI= 95.6% to 99.9%</td></tr><tr><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=2>100% (1/1)</td><td rowspan=1 colspan=2>95% CI= 20.7% to 100.0%</td></tr></table>

Table 7: Known Negative Specimens $( \mathrm { n } \mathrm { = } 2 0 0 )$ )   

<table><tr><td rowspan=2 colspan=1>LIAISON VZV IgG HT</td><td rowspan=1 colspan=3>Comparator</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>196</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>193</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>PPA*</td><td rowspan=1 colspan=2>0.0% (0/6)</td><td rowspan=1 colspan=2>95%CI= 0.0% to 39.0%</td></tr><tr><td rowspan=1 colspan=1>NPA*</td><td rowspan=1 colspan=2>97.9% (190/194)</td><td rowspan=1 colspan=2>95%CI= 94.8% to 99.2%</td></tr></table>

\* Equivocal results are counted against candidate device performance

Table 8: Pregnant Women Specimens $\mathrm { ( n = 1 } 3 5 \mathrm { ) }$ )   

<table><tr><td rowspan=2 colspan=1>LIAISON VZV IgG HT</td><td rowspan=1 colspan=3>Comparator</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>109</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>135</td></tr><tr><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>PPA*</td><td rowspan=1 colspan=2>98.2% (108/110)</td><td rowspan=1 colspan=2>95%CI= 93.6% to 99.5%</td></tr><tr><td rowspan=1 colspan=1>NPA*</td><td rowspan=1 colspan=2>96.0% (24/25)</td><td rowspan=1 colspan=2>95%CI= 80.5% to 99.3%</td></tr></table>

\* Equivocal results are counted against candidate device performance

Table 9: Laboratory Routine Specimens $( \mathrm { n } \mathrm { = } 1 0 8 3 ^ { \ast \ast }$ )   

<table><tr><td rowspan=2 colspan=1>LIAISON VZV IgG HT</td><td rowspan=1 colspan=3>Comparator</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>556</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>565</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>503</td><td rowspan=1 colspan=1>518</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>566</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>508</td><td rowspan=1 colspan=1>1083**</td></tr><tr><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>PPA*</td><td rowspan=1 colspan=1>556/571</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=2>95%CI= 95.7% to 98.4%</td></tr><tr><td rowspan=1 colspan=1>NPA*</td><td rowspan=1 colspan=1>503/512</td><td rowspan=1 colspan=1>98.2%</td><td rowspan=1 colspan=2>95%CI= 96.7% to 99.1%</td></tr></table>

\* Equivocal results are counted against candidate device performance \*\* 1 out of 1084 samples was excluded due to insufficient volume for testing on the candidate device.

# 2. Matrix Comparison:

A matrix equivalency study was conducted including 87 sets of matched reactive and nonreactive samples of different matrices (serum, with and without gel STT, dipotassium EDTA plasma, lithium-heparin plasma, and sodium heparin plasma) that were evaluated with the LIAISON VZV IgG HT assay. Data was analyzed using Passing Bablok fit regression comparing mean value results of all matrices to serum.

The following tube types are acceptable for use with the LIAISON VZV IgG HT assay: • Serum (with and without gel STT)   
• Plasma (dipotassium EDTA, lithium heparin, sodium heparin).

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity: Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

# D Clinical Cut-Off:

Not applicable

# E Expected Values/Reference Range:

Not Applicable

# F Other Supportive Instrument Performance Characteristics Data:

Not applicable

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.